IP Library › Granted Patent US 12,735,688
Granted Patent B2
US 12,735,688 · App. 18/335,481 · Granted Sep 15, 2026

Enzymes with RUVC domains

Inventors: Brian Thomas (Emeryville, CA); Christopher Brown (Emeryville, CA); Rose Kantor (Emeryville, CA); Audra Devoto (Emeryville, CA); Cristina Butterfield (Emeryville, CA); Lisa Alexander (Emeryville, CA); Daniela S. A. Goltsman (Emeryville, CA); Jason Liu (Emeryville, CA)
Assignee: Metagenomi Therapeutics, Inc.
C12N9/22C12N15/11C12Y301/21C12N2310/20C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,688
App. No.
18/335,481
Granted
Sep 15, 2026
Kind
B2
Abstract

The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

Claims (6)

1 . An engineered nuclease composition comprising:

(a) an endonuclease comprising a RuvC_III domain and an HNH domain, wherein said RuvC_III domain comprises a sequence having at least 85% sequence identity to at least 21 consecutive amino acids of SEQ ID NO: 2917 and wherein said HNH domain comprises a sequence having at least 85% sequence identity to at least 20 consecutive amino acids of SEQ ID NO: 4731; and

(b) an engineered guide ribonucleic acid structure configured to form a complex with said endonuclease comprising:

(i) a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and

(ii) a tracr ribonucleic acid sequence configured to bind to said endonuclease.

2 . The engineered nuclease composition of claim 1 , wherein said RuvC_III domain comprises a sequence having at least 90% sequence identity to at least 21 consecutive amino acids of SEQ ID NOs: 2917.

Assignments (4)
CHANGE OF NAME Recorded Feb 6, 2026
From: METAGENOMI, INC.
To: METAGENOMI THERAPEUTICS, INC.
Reel/Frame 073717/0149 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2025
From: CATALIO NEXUS FUND III, LP
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 073201/0168 →
SECURITY INTEREST Recorded Mar 4, 2025
From: AFFINI-T THERAPEUTICS, INC.
To: CATALIO NEXUS FUND III, LP
Reel/Frame 070403/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: THOMAS, BRIAN; BROWN, CHRISTOPHER; KANTOR, ROSE; DEVOTO, AUDRA; BUTTERFIELD, CRISTINA; ALEXANDER, LISA; GOLTSMAN, DANIELA S.A.; LIU, JASON
To: METAGENOMI, INC.
Reel/Frame 065404/0028 →
Continuity (12)
Continuation 17402426 · Aug 13, 2021
Continuation PCTUS2021031136 · May 6, 2021
Continuation PCTUS2020018432 · Feb 14, 2020
Provisional Application 63180570 · Apr 27, 2021
Provisional Application 63116155 · Nov 19, 2020
Provisional Application 63032464 · May 29, 2020
Provisional Application 63022320 · May 8, 2020
Provisional Application 62874414 · Jul 15, 2019
Provisional Application 62805878 · Feb 14, 2019
Provisional Application 62805899 · Feb 14, 2019
Provisional Application 62805868 · Feb 14, 2019
Related Publication 20240117330A1 · Apr 11, 2024
References Cited (178)
US 5858988A · Wang · 1999 [cited by applicant]
US 6291438B1 · Wang · 2001 [cited by applicant]
US 8889418B2 · Zhang et al. · 2014 [cited by applicant]
US 10011849B1 · Gill et al. · 2018 [cited by applicant]
US 10253365B1 · Doudna et al. · 2019 [cited by applicant]
US 10392607B2 · Sternberg et al. · 2019 [cited by applicant]
US 10913941B2 · Thomas et al. · 2021 [cited by applicant]
US 10982200B2 · Thomas et al. · 2021 [cited by applicant]
US 12024727B2 · Thomas et al. · 2024 [cited by applicant]
US 20140186919A1 · Zhang et al. · 2014 [cited by applicant]
US 20140186958A1 · Zhang et al. · 2014 [cited by applicant]
US 20140349405A1 · Sontheimer et al. · 2014 [cited by applicant]
US 20150045546A1 · Siksnys et al. · 2015 [cited by applicant]
US 20160362667A1 · Donohoue et al. · 2016 [cited by applicant]
US 20180312824A1 · Zhang et al. · 2018 [cited by applicant]
US 20180371498A1 · Gill et al. · 2018 [cited by applicant]
US 20190010471A1 · Zhang et al. · 2019 [cited by applicant]
US 20190062735A1 · Welstead et al. · 2019 [cited by applicant]
US 20190249200A1 · Seebeck et al. · 2019 [cited by applicant]
US 20190264232A1 · Hou et al. · 2019 [cited by applicant]
US 20200032240A1 · Wang et al. · 2020 [cited by applicant]
US 20200080067A1 · Zhang et al. · 2020 [cited by applicant]
US 20200263165A1 · Bendezu et al. · 2020 [cited by applicant]
US 20200302240A1 · Murata et al. · 2020 [cited by applicant]
US 20200332273A1 · Thomas et al. · 2020 [cited by applicant]
US 20200332274A1 · Thomas et al. · 2020 [cited by applicant]
US 20220033791A1 · Thomas et al. · 2022 [cited by applicant]
US 20220220460A1 · Thomas et al. · 2022 [cited by applicant]
US 20220298494A1 · Thomas et al. · 2022 [cited by applicant]
US 20220364067A1 · Lin et al. · 2022 [cited by applicant]
US 20220403357A1 · Zhang et al. · 2022 [cited by applicant]
US 20230051396A1 · Thomas et al. · 2023 [cited by applicant]
US 20240110167A1 · Thomas et al. · 2024 [cited by applicant]
US 20240209332A1 · Thomas et al. · 2024 [cited by applicant]
US 20240309356A1 · Thomas et al. · 2024 [cited by applicant]
US 20240344045A1 · Thomas et al. · 2024 [cited by applicant]
CA 3091267A1 · 2019 [cited by applicant]
CN 104520429A · 2015 [cited by applicant]
CN 105142669A · 2015 [cited by applicant]
CN 105209621A · 2015 [cited by applicant]
CN 112126661A · 2020 [cited by applicant]
EP 3141604A1 · 2017 [cited by applicant]
EP 3617311A1 · 2020 [cited by applicant]
EP 3854877A1 · 2021 [cited by applicant]
EP 4308699A1 · 2024 [cited by applicant]
JP 2019507599A · 2019 [cited by applicant]
JP 2019534695A · 2019 [cited by applicant]
JP 2022520428A · 2022 [cited by applicant]
WO WO2015066119A1 · 2015 [cited by applicant]
WO WO2016073990A2 · 2016 [cited by applicant]
WO WO2016141224A1 · 2016 [cited by applicant]
WO WO2016183041A2 · 2016 [cited by applicant]
WO WO2016186953A1 · 2016 [cited by applicant]
WO WO2016196655A1 · 2016 [cited by applicant]
WO WO2017152015A1 · 2017 [cited by applicant]
WO WO2017155714A1 · 2017 [cited by applicant]
WO WO2017193107 · 2017 [cited by applicant]
WO WO2018035250A1 · 2018 [cited by applicant]
WO WO2018041120A1 · 2018 [cited by applicant]
WO WO2018064352A1 · 2018 [cited by applicant]
WO WO2018073393A2 · 2018 [cited by applicant]
WO WO2018129346A1 · 2018 [cited by applicant]
WO WO2018172556A1 · 2018 [cited by applicant]
WO WO2018209712A1 · 2018 [cited by applicant]
WO WO2019097305A2 · 2019 [cited by applicant]
WO WO2019165168 · 2019 [cited by applicant]
WO WO2019161290A1 · 2019 [cited by applicant]
WO WO2019178421A1 · 2019 [cited by applicant]
WO WO2019200306A1 · 2019 [cited by applicant]
WO WO2020041120A1 · 2020 [cited by applicant]
WO WO2020057486A1 · 2020 [cited by applicant]
WO WO2020081613A1 · 2020 [cited by applicant]
WO WO2020150534A2 · 2020 [cited by applicant]
WO WO2020168122A1 · 2020 [cited by applicant]
WO WO2020168234A1 · 2020 [cited by applicant]
WO WO2020168291A1 · 2020 [cited by applicant]
WO WO2020236967A1 · 2020 [cited by applicant]
WO WO2021097118A1 · 2021 [cited by applicant]
WO WO2021202559A1 · 2021 [cited by applicant]
WO WO2021202568A1 · 2021 [cited by applicant]
WO WO2021226363A1 · 2021 [cited by applicant]
WO WO2021226369A1 · 2021 [cited by applicant]
WO WO2022056324A1 · 2022 [cited by applicant]
WO WO2022087494A1 · 2022 [cited by applicant]
Nishimasu, H., et al., Cell, vol. 156, Issue 5, p. 935-949, Feb. 27, 2014 (Year: 2014). [cited by examiner]
Parks, D., et al., Nature Biotechnology, vol. 36, p. 996-1004, Aug. 27, 2018 (Year: 2018). [cited by examiner]
Andronescu et al. Efficient Parameter Estimation for RNA Secondary Structure Prediction. Bioinformatics 23(13):i19-28 (2007). [cited by applicant]
Burstein et al.: New CRISPR-Cas systems from uncultivated microbes. Nature. 542(7640):237-241 (2017). [cited by applicant]
ctSKENNERTON: Mining CRISPRs in Environmental Datasets: Minced. GitHub URL:www.github.com/ctSkennerton/minced [1-4](2019). [cited by applicant]
Ding et al.: Recent Advances in Genome Editing Using CRISPR/Cas9. Front Plant Sci. 7:703:1-12 doi:10.3389/fpls.2016.00703 (2016). [cited by applicant]
Fang et al.: CRISPR/Cas9-mediated Genome Editing Technology. Progress in Biochemistry and Biophysics, 40(8):691-702 [with English Machine Translation] (2013). [cited by applicant]
Gasiunas et al. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. PNAS USA 109:E2579-E2586 (2012). [cited by applicant]
Guo et al.: Off-target effects and optimization strategies of CRISPR/Cas9 technology. Progress in Biochemistry and Biophysics, 45(8): 798-807 [with English Machine Translation] (2018). [cited by applicant]
Herdewijn: Heterocyclic modifications of oligonucleotides and antisense technology. Antisense & Nucleic Acid Drug Dev 10:297-310 (2000). [cited by applicant]
Huber et al. Orchestrating High-Throughput Genomic Analysis With Bioconductor. Nat Methods 12(2):115-21 (2015). [cited by applicant]
Jiang, F., et al., CRISPR—Cas9 Structures and Mechanisms, Annual Reviews Biophys., (2017), 46:505-529. [cited by applicant]
Jinek et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-821 (2012). [cited by applicant]
Kapitonov et al.: ISC, a Novel Group of Bacterial and Archaeal DNA Transposons That Encode Cas9 Homologs. J Bacteriol. 198(5):797-807 doi: 10.1128/JB.00783-15 (2015). [cited by applicant]
Karvelis et al. Methods for Decoding Cas9 Protospacer Adjacent Motif (PAM) Sequences: A Brief Overview. Methods 121-122:3-8 (2017). [cited by applicant]
Koonin et al. (2017) Diversity, classification and evolution of CRISPR-Cas systems. Current Opinion in Microbiology, 37:67-78 (Year : 2017). [cited by applicant]
Mali et al. RNA-guided human genome engineering via Cas9. Science 339(6121):823-826 (2013). [cited by applicant]
Mir et al.: Type II-C CRISPR-Cas9 Biology, Mechanism, and Application. ACS Chem Biol. 13(2):357-365 (2018). [cited by applicant]
Moon et al.: Recent advances in the CRISPR genome editing tool set. Exp Mol Med. 51(11):1-11 (2019). [cited by applicant]
NCBI GenBank Accession No. HHR99113.1, TPA: type II CRISPR RNA-guided endonuclease Cas9 [Acidobacteria bacterium] [1-2](2020). [cited by applicant]
NCBI GenBank Accession No. WP_061212298.1, HNH endonuclease [Dermabacter hominis] [1-2](2016). [cited by applicant]
NCBI GenBank: GBR72910.1—CRISPR-associated protein Csn1 family [Candidatus Termititenax aidoneus], pp. 1-3 (Oct. 31, 2019). [cited by applicant]
NCBI GenBank: WP_070675185.1—Multispecies: HNH endonuclease [unclassified Rothia (in: high G+C Gram-positive bacteria)], pp. 1-2 (Jan. 20, 2023). [cited by applicant]
NCBI GenBank: WP_070690139.1—HNH endonuclease [ [cited by applicant]
NCBI GenBank: WP_070847477.1—HNH endonuclease [ [cited by applicant]
NCBI Reference Sequence: RMH36335.1, hypothetical protein D66910_06140 [Nitrospirae bacterium], https://www.ncbi.nlm.nih.gov/protein/RMH36335.1/ [1-2](Published on Oct. 29, 2018). [cited by applicant]
PCT/US2020/018353 International Search Report and Written Opinion dated Jun. 30, 2020. [cited by applicant]
PCT/US2020/018432 International Search Report and Written Opinion dated Jun. 30, 2020. [cited by applicant]
PCT/US2021/024927 International Search Report and Written Opinion dated Jul. 21, 2021. [cited by applicant]
PCT/US2021/024945 International Search Report and Written Opinion mailed Jul. 20, 2021. [cited by applicant]
PCT/US2021/031136 International Search Report and Written Opinion dated Aug. 25, 2021. [cited by applicant]
PCT/US2021/031143 International Search Report and Written Opinion dated Aug. 25, 2021. [cited by applicant]
Rautela et al.: Efficient genome editing of human natural killer cells by CRISPR RNP. bioRxiv prePrint doi: https://doi.org/10.1101/406934 [1-24] (2018). [cited by applicant]
Schneider et al. Sequence logos: a new way to display consensus sequences. Nucleic acids research 18(20):6097-6100 (1990). [cited by applicant]
Shmakov et al. Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. Mol Cell 60(3):385-397 (2015). [cited by applicant]
Shmakov, et al.: Diversity and evolution of class 2 CRISPR-Cas systems. Nature Reviews Microbiology 15(3): 169-182 (2017). [cited by applicant]
Tang et al.: Class 2 CRISPR/Cas: an expanding biotechnology toolbox for and beyond genome editing. Cell Biosci. 8:59 doi:10.1186/s13578-018-0255-x [1-13](2018). [cited by applicant]
Tareen et al.: Logomaker: beautiful sequence logos in Python. Bioinformatics 6(7):2272-2274 (2020). [cited by applicant]
Uniprotkb/trembl: A0A1FOKNW4 ⋅ A0A1FOKNW4_9MICC HNHc domain-containing protein. [cited by applicant]
Uniprotkb/trembl: A0A1S1DADO ⋅ A0A1S1DADO_9MICC HNH Cas9-type domain-containing protein. [cited by applicant]
Uniprotkb/trembl: A1F0PN46 ⋅ A0A1F0PN46_9MICC HNH Cas9-type domain-containing protein. [cited by applicant]
U.S. Appl. No. 17/193,173 Final Office Action dated Apr. 17, 2023. [cited by applicant]
U.S. Appl. No. 17/857,923 Final Office Action dated Jun. 13, 2023. [cited by applicant]
U.S. Appl. No. 17/857,923 Non-Final Office Action dated Feb. 28, 2023. [cited by applicant]
U.S. Appl. No. 16/917,837 Office Action dated Aug. 26, 2020. [cited by applicant]
U.S. Appl. No. 16/917,838 Office Action dated Jul. 28, 2020. [cited by applicant]
U.S. Appl. No. 17/193,173 Non-Final Office Action dated Oct. 7, 2022. [cited by applicant]
Boel, A. et al., “CRISPR/Cas9-mediated homology-directed repair by ssODNs in zebrafish induces complex mutational patterns resulting from genomic integration of repair-template fragments”, [cited by applicant]
Gleditzsch, D. et al., “PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures”, [cited by applicant]
Leenay, R. et al., “Deciphering, Communicating, and Engineering the CRISPR PAM”, [cited by applicant]
Pingoud, A. et al., “Type II restriction endonucleases: structure and mechanism”, [cited by applicant]
Wu, X. et al., “Target specificity of the CRISPR-Cas9 system”, [cited by applicant]
Altae-Tran et al.: The widespread IS200/IS605 transposon family encodes diverse programmable RNA-guided endonucleases. Science. 374(6563):57-65 doi:10.1126/science.abj6856 (2021). [cited by applicant]
Bitard-Feildel, T. et al., “Order in Disorder as Observed by the Hydrophobic Cluster Analysis of Protein Sequences”, Proteomics, 2018, vol. 18, E1800054, pp. 1-12. [cited by applicant]
Carugo, O., Amino Acid Composition and Protein Dimension, Protein Science, Oct. 2008, vol. 17, No. 12, pp. 2187-2191. [cited by applicant]
Co-pending U.S. Appl. No. 18/053,232, inventors Thomas; Brian et al., filed Nov. 7, 2022. [cited by applicant]
Dyson, H.J., “Roles of intrinsic disorder in protein-nucleic acid interactions”, Mol Biosyst, 2011, vol. 8, No. 1, pp. 97-104. [cited by applicant]
Gasiunas, G. et al., “A catalogue of biochemically diverse CRISPR-Cas9 orthologs”, Nat Commun, 2020, vol. 11, No. 5512, pp. 1-10. [cited by applicant]
Harms, M. et al., “Analyzing protein structure and function using ancestral gene reconstruction”, Current Opinion in Structural Biology, 2010, vol. 20, No. 6, pp. 360-366. [cited by applicant]
Harris, K.A. et al., “Large Noncoding RNAs in Bacteria”, Microbiol Spectr, 2018, vol. 6, No. 4, pp. 1-18. [cited by applicant]
Katoh, K. et al., “MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability”, Molecular Biology and Evolution, 2013, vol. 30, No. 4, pp. 772-780. [cited by applicant]
Madshus, I.H.. “Regulation of intracellular pH in eukaryotic cells”, Biochemical Journal, 1988, vol. 250, No. 1, pp. 1-8. [cited by applicant]
Murthy, A.C. et al., “Molecular interactions underlying liquid-liquid phase separation of the FUS low complexity domain”, Nat Struct Mol Biol, 2019, vol. 26, No. 7, pp. 637-648. [cited by applicant]
Osorio, D. et al., “Peptides: A Package for Data Mining of Antimicrobial Peptides”, The R. Journal, 2015, 7(1), 4-14, pp. 1-11. [cited by applicant]
Price, M.N. et al., “Fast Tree2—Approximately Maximum-Likelihood Trees for Large Alignments”, PLOS One, 2010, vol. 5, No. 3, e9490, pp. 1-10. [cited by applicant]
Stamatakis, A., “RAxML Version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies”, Bioinformatics, 2014, vol. 30, No. 9, pp. 1312-1313. [cited by applicant]
U.S. Appl. No. 17/857,923 Advisory Action dated Aug. 8, 2023. [cited by applicant]
Weinberg, Z. et al., “Extraordinary Structured Noncoding RNAs Revealed by Bacterial Metagenome Analysis”, Nature 2009, vol. 462, No. 7273, pp. 656-659. [cited by applicant]
Xiao, N. et la., “protr/ProtrWeb: R package and web server for generating various numerical representation schemes of protein sequences”, Bioinformatics, 2015, vol. 31, No. 11, pp. 1857-1859. [cited by applicant]
Yang, Z., “PAML 4: Phylogenetic Analysis by Maximum Likelihood”, Molecular Biology and Evolution, 2007, vol. 24, No. 8, pp. 1586-1591. [cited by applicant]
Andronescu et al. Efficient Parameter Estimation for RNA Secondary Structure Prediction. Bioinformatics 23(13):i19-i28 (2007). [cited by applicant]
Corley , et al. How RNA-Binding Proteins Interact with RNA: Molecules and Mechanisms. Molecular Cell. 78(1):9-29 (2020). [cited by applicant]
GenPept Accession No. CAH11307. Version No. CAH11307.1. hypothetical protein Ipp0160 [Legionella pneumophila str. Paris]. Record created Oct. 3, 2004. pp. 1-2. Retrieved Jun. 10, 2024 at URL: https://www.ncbi.nlm.nih.go… [cited by applicant]
GenPept Accession No. WP_127108862. Version No. WP_127108862.1. type II-B CRISPR-associated RNA-guided endonuclease Cas9/Csx12 [ [cited by applicant]
Harrington, Lucas B. et al. Programmed DNA Destruction by Miniature CRISPR-Cas14 Enzymes. Science 362(6416):839-842 (2018). [cited by applicant]
Kortleve, D. et al. Orthotopic editing of T-cell receptors. Cell Therapy vol. 3: 949-950 (2019). [cited by applicant]
Makarova et al. Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 18(2):67-83 (2020). [cited by applicant]
NCBI GenBank: OGP48943.1—MAG: hypothetical protein A2022_01700 [Deltaproteobacteria bacterium GWF2_42_12], pp. 1-2 (Oct. 20, 2016). [cited by applicant]
Nowak et al. Guide RNA engineering for versatile Cas9 functionality. Nucleic Acids Res. 44(20):9555-9564 (2016). [cited by applicant]
Paix, et al. Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks. Proceedings of the National Academy of Sciences of the United States of America 114,50:E10745-E10754 (2017). [cited by applicant]
Ran, F. et al., In vivo genome editing using [cited by applicant]
Singh, et al. Protein Engineering Approaches in the Post-Genomic Era. Current Protein and Peptide Science 18:1-11 (2017). [cited by applicant]
UniProtKB Accession No. A0A3B9GP868. CRISPR-associated endonuclease Cas9. Record created Jan. 16, 2019. p. 1, Retrieved Jun. 10, 2024 at URL: https://www.uniprot.org/uniprotkb/A0A3B9GP86/entry. [cited by applicant]
UniProtKB, [online] Accession No. A0A1F8ZSN4, HNH nuclease domain-containing protein, Dec. 11, 2019, p. 1 [retrieved online Apr. 24, 2024], URL: https://rest.uniprot.org/unisave/A0A1F8ZSN4?format=txt&versions=11. [cited by applicant]
UniProtKB, [online] Accession No. AA0A3D 5Y812 and HNHc domain-containingprotein, Dec. 11, 2019, p. 1 [retrieved online Apr. 24, 2024], URL: https://rest.uniprot.org/unisave/A0A3D5Y812?format=txt&versions=6. [cited by applicant]
U.S. Appl. No. 17/193,173 Notice of Allowance dated Feb. 21, 2024. [cited by applicant]
U.S. Appl. No. 17/431,135 Office Action dated Jun. 4, 2024. [cited by applicant]
Xu, Daohua. Tigit Cas9-KO Strategy. GenPharmatech Co, Ltd., Retrieved at URL: https://oss.gempharmatech.com/upload/file/20240324/T012735.Tigit%20Cas9-KO%20%20Strategy-EN.pdf, 11 pages (2019). [cited by applicant]
Xu, et al. Efficient genome engineering in eukaryotes using Cas9 from [cited by applicant]
Yan et al., Functionally diverse type V CRISPR-Cas systems. Science 363: 88-91 (2019). [cited by applicant]
Yang et al.: New CRISPR-Cas systems discovered. Cell Res. 27(3):313-314 doi:10.1038/cr.2017.21 (2017). [cited by applicant]
Zhang et al. Propagated Perturbations from a Peripheral Mutation Show Interactions Supporting WW Domain Thermostability. Structure 26(11):1474-1485 (2018). [cited by applicant]
Zhou, X.M. et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells. Front. Immunol. vol. 9, Article 2821: 1-11 (2018). [cited by applicant]
Database Genbank [on line], Accession No. LTTT01000045.1, 2016 [retrieved on Jul. 25, 2025], hypothetical protein HMPREF2999_08435 [ [cited by applicant]